Juergen Alt
5 Papers
Juergen Alt is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
Melanie Janning,Juliane Süptitz,C. Albers-Leischner,P Delpy,Amanda Tufman,Janna-Lisa Velthaus-Rusik,Martin Reck,Alex Jung,Diego Kauffmann-Guerrero,Irina Bonzheim,Stephanie Brändlein,Horst Hummel,Marcel Wiesweg,H. U. Schildhaus,Jan Stratmann,M. Sebastian,Juergen Alt,Jessie E. Buth,I. Esposito,J. Berger,Lars Tögel,Felix C Saalfeld,Martin Wermke,Sabine Merkelbach-Bruse,Axel M. Hillmer,Frederick Klauschen,Carsten Bokemeyer,Reinhard Buettner,Jonathan Wolf,Sonja Loges +29 more
TL;DR: In this paper , a multicenter study of the national Network Genomic Medicine (nNGM) in Germany, 856 NSCLC cases with atypical EGFR mutations including co-occurring mutations were reported from 12 centers.
74
681P OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck – AIO-KHT-0117
Victor Gruenwald,Juergen Alt,Mareike Tometten,Mathias Haenel,Philipp Ivanyi,Gunter Schuch,Konrad Klinghammer,Katrin Gutsche,Justin Hasenkamp,Gunnar Hapke,Martin Mänz,Wilko Weichert,Dennis Hahn +12 more
TL;DR: In this paper , the authors evaluated whether escalated therapy targeting PD-1 and CTLA-4 is superior to docetaxel (DOC) in nivolumab-refractory patients.
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment (PACE).
Jan Stratmann,Fabian Acker,Lukas Aspacher,Juergen Alt,Fr Althoff,Sophie Heinzen,Nicola Gökbuget,Ina Müller,Lena Reiser,Sina Hehn,Hubert Serve,Martin Mänz,Frauke Meyer,Martin Sebastian +13 more
TL;DR: The primary outcome measure of the trial is progression-free survival (PFS), with the objective to assess the efficacy of biomarker-driven escalation of osimertinib therapy with a combination platinum-based regimen.
EP14.01-008 Checkpoint Inhibitors Prevent New Onset of Brain Metastases in Relapsed Extensive Disease Small-Cell Lung Cancer
Jan Stratmann,L. schäfer,Fr Althoff,Fabian Acker,L. Aguinate,Silvina Heinzen,Akin Atmaca,V. Rosery,Juergen Alt,Cornelius F. Waller,Niels Reinmuth,G. Rohde,Felix C Saalfeld,Aaron Becker von Rose,Miriam Möller,Nikolaj Frost,M. Sebastian +16 more
TL;DR: In this article , the authors show that checkpoint inhibitors (CPI) have activity against brain metastases from melanoma and non-small cell lung cancer, however, data in SCLC are lacking.
Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.
Philipp Stenzel,Mario Schindeldecker,Katrin E. Tagscherer,Sebastian Foersch,Esther Herpel,Markus Hohenfellner,Gencay Hatiboglu,Juergen Alt,Christian Thomas,Axel Haferkamp,Wilfried Roth,Stephan Macher-Goeppinger +11 more
TL;DR: This study shows that subsets of tumor-infiltrating leukocytes in the TME and also PD-1/PD-L1 provide prognostic and predictive information for patients with ccRCC.